AI gen brain scan concept
Adobe Stock
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

Telix Pharmaceuticals (ASX:TLX) has announced its receipt of fast track status from the US FDA within the approvals chain for the assessment of Telix’s PET-scan brain cancer imaging agent Pixclara.

The company is focusing particularly on gliomas in the brain – a tumour that forms from glial cells acting abnormally. Glial cells help connect neurons in the brain, making ‘glioma’ and ‘brain cancer’ effectively interchangeable.

Fast track status does not guarantee eventual commercialisation approval from the United States’ food and drug regulator but does ensure a relatively faster progression through the bureaucratic ecosystem.

Pixclara – F-floretyrosine (or, F-FET) – is designed for injection into the human body before a PET scan. Imaging agents are, in pub language, lightly radioactive materials that ‘show up’ on scanners, allowing a high-definition scan of the internal anatomy of a patient.

Telix noted on Wednesday its fast track status win is due to a relative lack of treatment viability in glioma patients.

“With low survival rates and the need to make rapid decisions, precision imaging is paramount,” Telix wrote on Wednesday.

“Pixclara is also being developed as the “companion” theranostic imaging agent for TLX101, Telix’s investigational neuro-oncology drug candidate,” the company added.

Management further outlined the dire situation most patients face at present.

“Gliomas are the most common primary brain tumours of the central nervous system. Conventional imaging with MRI6 often yields inconclusive results in characterising recurrent disease and therefore delays time-sensitive decision making,” Telix CEO Kevin Richardson said.

“Limitations of conventional imaging techniques include the lack of biological specificity, dependency on blood-brain barrier disruption, and an inherent inability to differentiate between tumour progression or treatment-related causes.”

TLX last traded at $19.97.

TLX by the numbers
More From The Market Online
Disability NDIS concept

Freedom Care Group reveals NDIS wants to ban it providing program services

Shares in Freedom Care Group (ASX:FCG) were down more than -3% on Wednesday after revealing the…
Small pile of rare earth minerals

Critica confirms high grade REE mineralisation at Jupiter with 3,074 ppm intercept

Critica Ltd has confirmed high grade REE mineralisation at the Jupiter target, part of the larger…
AI gen vanadium flow battery concept

Aussie Vanadium unveils vision for a 100MW modular vanadium flow battery

Australian Vanadium has kicked off Project Lumina, seeking to build a modular 100MW Vanadium Flow Battery…
Crosse section of the earth

Earths Energy confirms Paralana as an Enhanced Geothermal Systems Program project

Earths Energy Ltd has completed preliminary work on its Techno Economic Feasibility study for the Paralana…